F-star and Denali Therapeutics to develop a multispecific antibody platform

25 August 2016
2019_biotech_test_vial_discovery_big

UK-based biotech firm F-star has announces a collaborative agreement with the US start-up Denali Therapeutics to research and develop antibodies for the delivery of medicines across the blood-brain barrier (BBB) into the central nervous system (CNS).

Under the accord, Denali will make an upfront payment to F-star of $6 million. Denali also has the option to acquire F-star Gamma (F-star's latest asset centric vehicle) prior to the initiation of the first Phase I clinical trial in return for aggregate exercise and milestone payments to the F-star Gamma shareholders of up to $450 m in total.

If Denali does not exercise the option, it has the right it license a number of MAb based on each Fcab generated by F-star Gamma, in return for license fees, development, regulatory and commercial milestones payments with a potential aggregate value of $1 billion and tiered royalties on product sales.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology